Fierce Pharma

SEPTEMBER 21, 2023

Looking to establish a “hub” in the cell therapy ecosystem, the Novo Nordisk Foundation is pumping 950 million Danish kroner (about $136 million) into a new clinical production site at the Technica | Looking to establish a “hub” in the cell therapy ecosystem, the Novo Nordisk Foundation is pumping 950 million Danish kroner (about $136 million) into a new clinical production site at the Technical University of Denmark (DTU) in Lyngby.

Manufacturing 327

Manufacturing 327

David Bagga

SEPTEMBER 21, 2023

The Medical device sales industry is a well-known career destination that hundreds of thousands of candidates are trying to break into everyday. Medical Device Sales Career Home Blog The Right Profile & Path to take to Breaking into MDS The Right Profile & Path to take to Breaking into Medical Device Sales The Medical device […] The post The Right Profile & Path appeared first on.

Sales 130

Sales Medical Medical sales reps Medical sales 130

Fierce Pharma

SEPTEMBER 21, 2023

Long categorized as a takeover target, autoimmune disease specialist Aurinia Pharmaceuticals has remained independent, to the frustration of some investors who believe the Canadian company has not | Aurinia has responded to criticism from some investors who believe the company has not maximized its opportunity with lupus nephritis drug Lupkynis. The company named its founder and former CEO Robert Foster to its board of directors in an agreement with major stockholder MKT Capital.

Pharmaceutical 232

Pharmaceutical 232

MedCity News

SEPTEMBER 21, 2023

As hospitals across the nation adopt more and more AI technology, there are some common hazards of which they should be wary. During a conference presentation on Tuesday, healthcare AI expert Suchi Saria laid out seven AI pitfalls hospitals should look out for — some of these include being duped by Big Tech companies’ marketing strategies and focusing too much on administrative use cases.

Healthcare 121

Healthcare Healthcare Marketing 121

Advertisement

Distribution

Fierce Pharma

SEPTEMBER 21, 2023

Even after Eli Lilly missed its first swing at the lucrative U.S. market with ulcerative colitis drug mirikizumab, the company’s launch is gaining steam overseas. | Lilly's mirikizumab is one of several launches the company is counting on for growth in the near term. Even after an FDA rejection, the launch is gaining steam overseas.

FDA 219

FDA Marketing 219

MedCity News

SEPTEMBER 21, 2023

Thirty states have been conducting Medicaid and CHIP automatic renewals incorrectly, leading to many individuals being wrongly removed from coverage. Because of this, nearly 500,000 children and other individuals will have their coverage reinstated.

Leads 114

Leads 114

MedCity News

SEPTEMBER 21, 2023

Americans are getting older, and some healthcare leaders expect this to be a challenge for the healthcare industry. Others, however, think this is an opportunity for the industry to make improvements, such as engaging adults in their care before they turn 65.

Healthcare 114

Healthcare Healthcare 114

Fierce Pharma

SEPTEMBER 21, 2023

Takeda has managed to close one of the antitrust cases that have been hanging over the company. | Takeda has managed to close one of the antitrust cases that have been hanging over the company. The Japanese pharma giant has inked a settlement with drug wholesalers who accused the company of using anti-competitive deals to delay generic entry to its gout drug Colcrys.

Competition 202

Competition Management Pharma 202

PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The recent announcement of the first 10 drugs selected for price negotiations is a significant first step in Medicare’s effort to directly set drug prices for seniors.

Manufacturing 111

Manufacturing Competition Marketing Physicians 111

Fierce Pharma

SEPTEMBER 21, 2023

In a patent case centered on two rival hemophilia medicines, Roche's Genentech unit has scored its second straight win. | After Takeda's Baxalta unit moved to appeal a prior loss, the U.S. federal appeals court backed the decision in favor of Roche.

Medicine 180

Medicine 180

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

PM360

SEPTEMBER 21, 2023

Pity the poor pharma brand marketer. Over the past many years, they’ve seen their colleagues on the performance marketing side grow in influence and sophistication as their datasets and digital channels have expanded their value to the business. In contrast, brand marketing can feel like a vestige from another era of marketing, poorly understood, with poor metrics, and little consensus of how brand marketing contributes to the overall business.

Pharma 111

Pharma Marketing Prescription Media 111

Fierce Pharma

SEPTEMBER 21, 2023

In this episode of "The Top Line," Annalee Armstrong and Gabrielle Masson shine a spotlight on some of the most promising companies in the biotech world. | In this episode of "The Top Line," we shine a spotlight on some of the most promising companies in the biotech world and do a deep dive into drug commercialization strategies.

130

130

MedCity News

SEPTEMBER 21, 2023

Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.

Biopharma 109

Biopharma 109

Fierce Pharma

SEPTEMBER 21, 2023

BeiGene and Novartis have parted ways on the PD-1 drug tislelizumab. Roche's Genentech signed a radiopharmaceutical-peptide conjugate deal with Japan's PeptiDream. | BeiGene and Novartis have parted ways on the PD-1 drug tislelizumab. Roche's Genentech signed a radiopharmaceutical peptide conjugate deal with Japan's PeptiDream. Biocon named a new group CEO.

Pharma 130

Pharma 130

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

European Pharmaceutical Review

SEPTEMBER 21, 2023

A new Denmark-based manufacturing facility is set to establish the final development steps and upscaling of cell therapies. To establish it, the Novo Nordisk Foundation is committing up to £127 million. CEO of the Novo Nordisk Foundation Cellerator, Thomas HR Carlsen, told EPR that for cell therapy manufacturing, “The biggest challenge is producing high-quality, consistent cell therapies at the scale required for use in clinical trials… biological complexity [of living cells] means that the man

Manufacturing 109

Manufacturing Leads Networking Pharmaceutical 109

MedCity News

SEPTEMBER 21, 2023

Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year.

Prospecting 107

Prospecting FDA Biopharma Pharma 107

PM360

SEPTEMBER 21, 2023

Some things are better together. While field force activities and digital advertising can be powerful on their own, timely coordination of the two can create an even greater business impact. This “synchronization” helps biopharmas such as Pfizer maximize marketing and field efforts across their organizations to improve engagement with healthcare professionals (HCPs).

Marketing 105

Marketing Media CRM Sales 105

MedCity News

SEPTEMBER 21, 2023

This article explores the benefits of implementing RFID in healthcare settings and how hospitals can gradually transition from barcode to RFID-enabled medication systems, leading to substantial cost savings and improved patient care.

Medical 103

Medical Healthcare Healthcare Leads 103

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

PM360

SEPTEMBER 21, 2023

Last we spoke, executing omnichannel digital media using programmatic as the foundation was the topic. But we cannot talk about the media channels and how to connect them without talking about the creative. It has an outsized impact on your media plans’ performance and we need it to drive success. According to Ipsos, 75% of campaign success is driven by the creative.

Media 105

Media Digital Media Marketing Pharma 105

Pharmaceutical Technology

SEPTEMBER 21, 2023

The US FDA has accepted Takeda’s NDA resubmission for TAK-721 for the short-term treatment of eosinophilic esophagitis (EoE), for review.

FDA 116

FDA 116

PM360

SEPTEMBER 21, 2023

A wave of blockbuster generic drugs launches, new brand drugs that address unmet needs, and legislation that would bring transparency to the pharmacy benefit manager (PBM) industry are just some of the developments that managed care pharmacy leaders are watching closely this year. Jeff Casberg, MS, RPh, Senior Vice President of Clinical Pharmacy at IPD Analytics, a managed care and pharmaceutical consultancy, highlighted a wide range of 2023 key events that will affect managed care professionals

Management 105

Management Manufacturing Sales Competition 105

European Pharmaceutical Review

SEPTEMBER 21, 2023

A new report published by the Center for Global Development (CGD) has highlighted the need for coordinated global action against antimicrobial resistance (AMR). Experts from organisations such as the Wellcome Trust and Africa Centres for Disease Control and Prevention contributed to the paper, urging governments, industry and international organisations to create a political agreement, or ‘Grand Bargain’, to improve innovation, access, and stewardship for antimicrobials, particularly in low- and

Pharma 99

Pharma Government Marketing Manufacturing 99

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

PM360

SEPTEMBER 21, 2023

Patients living with chronic obstructive pulmonary disease (COPD) need help having earlier, more honest, and more effective conversations with their doctors about their illness. That’s one key takeaway from a recent survey of more than 1,000 patients, the findings of which suggest that inadequate patient-provider communication may be a contributing factor to poorer quality of life for COPD patients.

Doctors 104

Doctors Patients Education Physicians 104

Referral MD

SEPTEMBER 21, 2023

Artificial Intelligence (AI) has enormous potential to revolutionize the medical industry, leading to better patient outcomes, more efficient diagnoses, and improved workflows. One area where AI can make an impactful difference is streamlining the referral process for doctors and patients, reducing wait times, and improving the overall quality of healthcare.

Doctors 95

Doctors Healthcare Provider Healthcare Healthcare 95

PM360

SEPTEMBER 21, 2023

The recent wave of Alzheimer’s Disease (AD) drug approvals and promising pivotal trial data from various drug manufacturers has been celebrated by physicians, patients, caregivers, and advocacy groups across the U.S. The scientific breakthroughs that led to these new therapies came after decades of research in AD and studies of more than 200 drug candidates.

Manufacturing 99

Manufacturing FDA Recruitment Prospecting 99

MedCity News

SEPTEMBER 21, 2023

A human touch makes a significant difference in healthcare call interactions where an automation-dominant approach would fall short.

Healthcare 109

Healthcare Healthcare 109

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

PM360

SEPTEMBER 21, 2023

As the drug landscape grows increasingly competitive, it will be vital to gain an intimate, personalized understanding of how individual patients respond to medication to highlight a drug’s value on their quality of life. Digital biomarkers powered by artificial intelligence (AI) are already providing critical insights to personalize care and draw more comprehensive conclusions about a therapy’s impact.

Competition 91

Competition Medicine Medical Patients 91

PharmaTech

SEPTEMBER 21, 2023

FUJIFILM Diosynth Biotechnologies has finished its new viral vector gene therapy manufacturing facility in Darlington, United Kingdom.

Manufacturing 98

Manufacturing 98

PharmaTimes

SEPTEMBER 21, 2023

The report outlines ways the government can help patients with Parkinson’s disease - News - PharmaTimes

Government 105

Government Safety Patients 105

Pharmaceutical Technology

SEPTEMBER 21, 2023

Kezar and Everest Medicines have signed a deal for the development and commercialisation of zetomipzomib for lupus nephritis.

Medicine 98

Medicine 98

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management